BeOne Medicines
ONC
#769
Rank
HK$252.17 B
Marketcap
HK$2,431
Share price
0.20%
Change (1 day)
30.00%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeOne Medicines (ONC)

EPS in 2026 (TTM): HK$37.61

According to BeOne Medicines's latest financial reports the company's current EPS (TTM) is HK$37.68. In 2025 the company made an earnings per share (EPS) of HK$21.39 an increase over its 2024 EPS that were of -HK$48.89.

EPS history for BeOne Medicines from 2015 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$37.6175.85%
2025HK$21.39-143.75%
2024-HK$48.89
2022-HK$152.7728.21%
2021-HK$119.16-19.96%
2020-HK$148.8820.81%
2019-HK$123.2331.52%
2018-HK$93.70417.57%
2017-HK$18.10-37.16%
2016-HK$28.81158.95%
2015-HK$11.13

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
OPKO Health
OPK
-HK$1.88-104.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$7.44-119.75%๐Ÿ‡บ๐Ÿ‡ธ USA